Please login to the form below

Not currently logged in
Email:
Password:

Eli Lily

This page shows the latest Eli Lily news and features for those working in and with pharma, biotech and healthcare.

Biohaven gets FDA approval for migraine drug Nurtec ODT

Biohaven gets FDA approval for migraine drug Nurtec ODT

Once launched it will also have to compete with Eli Lily’s new acute migraine therapy Reyvow (lasmiditan), a first-in-class 5H-T.

Latest news

  • Nine positive opinions for new drugs at CHMP meeting Nine positive opinions for new drugs at CHMP meeting

    Another medicine for lung cancer, Portrazza (necitumumab) from Eli Lilly, was also backed by the CHMP for the treatment of squamous NSCLC.

  • Building brand strength – Part 1 Building brand strength – Part 1

    We have seen products such as Viagra, Prilosec and Lipitor along with some corporate names (eg, Eli Lily, Pfizer and Merck) nominated in our Iconic Brands survey.

  • Positive phase IV results for Zyvox

    Data from the study showed that Zyvox achieved a statistically significantly higher clinical success rate compared with vancomycin, which was first marketed as vancomycin hydrochloride by Eli Lily under the trade

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Both analysts and academics had been getting excited about the Expedition 3 trial of Eli Lilly’s solanezumab, which has been developed to target amyloid-beta - the protein that clumps together

  • Who tops the pharma list? Who tops the pharma list?

    For example, patents for Seroquel (AstraZeneca - 2011 revenues of $5.8bn), Zyprexa (Eli Lily - $4.6bn) and Concerta (J&J - $1.3bn) had all expired by May 2012.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    In July 2012, Eli Lilly opened a diabetes research centre in Shanghai. ... These include GSK's alliance with Binnopharm in Russia, Roche's partnership with Encure Pharmaceuticals to develop affordable versions of Herceptin and MabThera in India, and Eli

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....